Senores Pharmaceuticals FY26 Revenue Up 62% PAT 108%

Senores Pharmaceuticals reported strong FY26 results with revenue growth of 62% to INR664 crore and PAT growth of 108% to INR122 crore.
Management provided FY27 guidance for 30-40% revenue growth and 50-60% PAT growth, supported by 30 upcoming ANDA launches.
The company completed 75% acquisition of Apnar Pharma, adding USFDA-approved manufacturing capacity expected to generate INR80-100 crore revenue in FY27.
Emerging markets business achieved 18-19% EBITDA margin in Q4 and turned cash flow positive, while US regulated market revenue grew 83% YoY.